⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23819447 | 1.00 | — | — | |
| SCHEMBL12182876 | 1.00 | — | — | |
| SCHEMBL15833834 | 0.78 | ALDH1A1 (0.34) | — | |
| SCHEMBL13862874 | 0.78 | ALDH1A1 (0.34) | — | |
| SCHEMBL18567596 | 0.78 | ALDH1A1 (0.34) | — | |
| SCHEMBL15951624 | 0.77 | CYP1A2 (0.34) | — | |
| SCHEMBL18407247 | 0.77 | CYP1A2 (0.34) | — | |
| SCHEMBL24445527 | 0.77 | CYP1A2 (0.34) | — | |
| SCHEMBL15214950 | 0.76 | — | — | |
| SCHEMBL11985321 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021183790-A1 | METHOD FOR TREATMENT OF COVID-19-ASSOCIATED CONDITIONS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-09-16 | — | — | WO | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-7989448-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7563892-B1 | Prodrugs of 2,4 pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7538108-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20090124580-A1 | Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades | RIGEL PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |